ORCA Therapeutics Overview

  • Founded
  • 2005
  • Status
  • Private
  • Employees
  • 4
  • Latest Deal Type
  • Grant
  • Investors
  • 5

ORCA Therapeutics General Information


Developer of oncolytic virus immunotherapeutic drugs designed to improve the lives of prostate cancer patients. The company's drugs use viruses to cure cancer and helps to engineer powerful oncolytic adenoviruses that selectively kill cancer cells and induce an antitumor immune response, enabling cancer patients to get immunotherapies to fight prostate cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • P.O. Box 3061
  • 5203 DB Hertogenbosch
  • Netherlands
+31 073 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ORCA Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 04-May-2016 00.000 Completed Generating Revenue
3. Later Stage VC 01-Apr-2016 00.000 00.000 Completed Generating Revenue
2. Seed Round 05-May-2013 Completed Generating Revenue
1. Grant 08-Nov-2011 $6.92M Completed Generating Revenue
To view ORCA Therapeutics’s complete valuation and funding history, request access »

ORCA Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Jan van der Hoeven Chief Financial Officer
Wenliang Dong Chief Operating Officer
Victor van Beusechem Chief Scientific Officer
Kees Groen Ph.D Chief Executive Officer
Ari Aminetzah Chief Business Officer
You’re viewing 5 of 6 executive team members. Get the full list »

ORCA Therapeutics Board Members (4)

Name Representing Role Since
Jan Egberts MD Self Board Member 000 0000
Karl Rothweiler Aglaia Management B.V. Board Member 000 0000
Mark Krul Ph.D Aglaia Management B.V. Board Member 000 0000
You’re viewing 3 of 4 board members. Get the full list »

ORCA Therapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ORCA Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Horizon 2020 Government 000 0000 000000 0
Aglaia Management B.V. Venture Capital Minority 000 0000 000000 0
Oost NL Venture Capital Minority 000 0000 000000 0
Government of the Netherlands Government 000 0000 000000 0
SenterNovem Corporation 000 0000 000000 0
To view ORCA Therapeutics’s complete investors history, request access »